aTENSION.life, a Vienna, Austria-based high-tech life science startup developing precision diagnostics for hypertension, raised USD 3m in seed financing.
The round was led by Wlanholding, with participation from eQventure and VP Venture Partners. In conjunction with the funding, Dr. Werner Lanthaler, Founder and CEO of Wlanholding GmbH, has been appointed Chairman of the Supervisory Board at aTENSION.life.
aTENSION.life has developed a proprietary ALDO+ technology platform that makes advanced mass spectrometry-based diagnostics accessible to patients with uncontrolled hypertension. The company’s first product, ALDO+PA, screens for primary aldosteronism, a significantly underdiagnosed condition affecting 5-10% of all hypertensive patients.
The ALDO+PA test is currently available in Austria through a partnership with labors.at and is planned to roll out across DACH markets by 2026, with first customers already implementing the technology in Germany, Switzerland, and the US.
Dr. Lanthaler will provide strategic guidance to aTENSION.life’s newly announced management team: Bernhard Klemen (CEO), Marko Poglitsch (CSO), and Katharina Wieser (CBO).
FinSMEs
08/05/2025